Invention Grant
- Patent Title: Universal anti-CD22 chimeric antigen receptor engineered immune cells
-
Application No.: US16498899Application Date: 2018-03-30
-
Publication No.: US11944643B2Publication Date: 2024-04-02
- Inventor: Julianne Smith , Philippe Duchateau , Murielle Derrien
- Applicant: CELLECTIS SA
- Applicant Address: FR Paris
- Assignee: CELLECTIS SA
- Current Assignee: CELLECTIS SA
- Current Assignee Address: FR Paris
- Agency: Casimir Jones, S.C.
- Agent Peter J. Schlueter
- Priority: DK 201770239 2017.03.31 DK 201770240 2017.03.31 DK 201770542 2017.06.30 WO TEP2017076800 2017.10.19
- International Application: PCT/EP2018/058367 2018.03.30
- International Announcement: WO2018/178377A 2018.10.04
- Date entered country: 2019-09-27
- Main IPC: A61K35/17
- IPC: A61K35/17 ; A61K31/365 ; A61K39/395 ; A61P35/02 ; C07K14/705 ; C07K14/725 ; C07K16/28
Abstract:
The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.
Public/Granted literature
- US20210161954A1 UNIVERSAL ANTI-CD22 CHIMERIC ANTIGEN RECEPTOR ENGINEERED IMMUNE CELLS Public/Granted day:2021-06-03
Information query
IPC分类:
